Medical Condition News

RSS

SCT transplantation benefits in Hodgkin's lymphoma is unclear

It remains an unresolved question whether adult patients with Hodgkin's lymphoma, a certain type of lymph node cancer, benefit from allogeneic stem cell transplantation (SCT) with an unrelated donor. This is due to the fact that studies are lacking that compare this therapy with autologous transplantation or conventional chemotherapy without SCT.

30 Sep 2010

ACT updates myoblast program for heart failure treatment

Advanced Cell Technology, a leader in the field of regenerative medicine, provided an update today on the status of its myoblast program. The program has successfully and safely completed Phase I human clinical trials in more than forty patients in over four independent studies.

30 Sep 2010

USFDA grants Sun Pharma subsidiary tentative approval for generic Crestor ANDA

Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary a tentative approval for its Abbreviated New Drug Application (ANDA) to market a generic version of IPR Pharmaceutical's Crestor ® tablets 5 mg, 10 mg, 20 mg, 40 mg.

30 Sep 2010

Study shows blueberries may help fight atherosclerosis

Blueberries may help fight atherosclerosis, also known as hardening of the arteries, according to results of a preliminary U.S. Department of Agriculture funded study with laboratory mice. The research provides the first direct evidence that blueberries can help prevent harmful plaques or lesions, symptomatic of atherosclerosis, from increasing in size in arteries.

30 Sep 2010

Duke receives approval to initiate NPC-1C Phase I trial for advanced pancreatic and colorectal cancer

Neogenix Oncology, Inc. announced today that researchers at Duke University Medical Center have received approval to move forward with a Phase I trial of the company's lead therapeutic antibody, NPC-1C, in patients with advanced stage pancreatic or colorectal cancer. Duke joins Johns Hopkins Hospital which is already conducting the Phase I trial of NPC-1C. In addition to Johns Hopkins, North Shore - LIJ has also enrolled patients on this multi-center study.

30 Sep 2010

Stress-factors leading to mental problems and burnout in IT-industries

According to health insurances, employees in IT-industries are very fit. By using an online-survey, Technische Universität Dortmund monitored this statement in cooperation with some freelancer-networks. Results indicate that this is due to the phenomenon "presentism"- meaning IT-employees do not appear in health insurance statistics as they continue to work even when they are ill. Actually, the sample reported on distinct health problems- predominantly musculoskeletal problems and mental afflictions.

30 Sep 2010

Scientists discover gut stem cells replacement mechanism

CANCER RESEARCH UK scientists have discovered that gut stem cells replace each other in a 'one in, one out' system, which is completely different to previously accepted theories.

30 Sep 2010

New immunotherapy regimen improves survival rate in children with neuroblastoma: Research

Administering a new form of immunotherapy to children with neuroblastoma, a nervous system cancer, increased the percentage of those who were alive and free of disease progression after two years, according to researchers at the University of California, San Diego School of Medicine and fellow institutions.

30 Sep 2010

UNC scientists receive grant to develop targeted delivery system for pancreatic cancer

A team of UNC scientists has received a five-year $2,308,800 grant from the National Cancer Institute's Cancer Nanotechnology Platform Partnerships to address the critical need for early diagnosis of and more effective treatments for pancreatic cancer.

30 Sep 2010

Michigan University researchers receive funds to study breast cancer risk factors

A team of researchers led by a Michigan State University scientist has been awarded $14 million to identify risk factors for breast cancer in young women, focusing on growth, diet, physical activity and body size during a woman's lifetime.

30 Sep 2010

Memantine enhances language and communication skills in patients with Alzheimer's disease

Memantine enhances language and communication skills in patients with moderate to severe Alzheimer’s disease (AD), a valuable contribution for patient independence and quality of life for both the patient and the family/caregivers. These are the findings discussed at the 14th Congress of the European Federation of Neurological Societies (EFNS).

30 Sep 2010

Circadian partners with Cincinnati Children's Hospital to develop blood test diagnostic for LAM, a serious lung disease

Circadian Technologies (ASX.CIR) has announced today that it has partnered with Cincinnati Children’s Hospital Medical Centre (CCHMC) to develop and market a blood test to diagnose LAM, a serious lung disease that strikes women, usually in their child bearing years.

29 Sep 2010

Keryx commences Zerenex Phase 3 study for hyperphosphatemia in patients with ESRD on dialysis

Keryx Biopharmaceuticals, Inc. announced today the initiation of the long-term Phase 3 study of Zerenex™ (ferric citrate), the Company's iron-based phosphate binder for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis.

29 Sep 2010

NINDS establishes new sites as part of Morris K. Udall Centers of Excellence in Parkinson's Disease Research

The National Institute of Neurological Disorders and Stroke (NINDS), a component of the National Institutes of Health, has established two new sites as part of the Morris K. Udall Centers of Excellence in Parkinson's Disease Research. The NINDS grants will provide a five-year investment totaling more than $16 million for Emory University in Atlanta and the Feinstein Institute for Medical Research in Manhasset, N.Y.

29 Sep 2010

Rigel earns $25M milestone payment from Astrazeneca for clinical development of fostamatinib

Rigel Pharmaceuticals, Inc. today announced that it has earned $25 million from AstraZeneca for the fulfillment of two major milestones in the agreement the two companies have regarding the clinical development of fostamatinib (R788), a novel oral syk inhibitor. The first milestone is for initiation of the phase 3 clinical program with fostamatinib in patients with rheumatoid arthritis (RA) that was announced by AstraZeneca earlier today.

29 Sep 2010

IN.PACT drug-eluting balloons show promising results for superficial femoral artery disease treatment

Advancing research on drug-eluting balloons for the treatment of coronary and peripheral artery disease, Medtronic, Inc., today announced the latest results from the IN.PACT drug-eluting balloon (DEB) clinical program presented last week at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 conference.

29 Sep 2010

Pulmokine receives NIH SBIR grants to develop novel treatments for PAH

YM BioSciences Inc., today reported that Pulmokine Inc. (Slingerlands, New York), a licensee of several small molecule compounds from YM, has been awarded two National Institutes of Health (NIH) Small Business Innovation Research (SBIR) grants. The grants, totaling more than US$650,000, are Phase I awards to develop novel treatments for Pulmonary Arterial Hypertension (PAH).

29 Sep 2010

XOMA completes patient enrollment in XOMA 052 Phase 2a trial

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that patient enrollment was recently completed for the company's Phase 2a trial of XOMA 052 in patients with Type 2 diabetes.

29 Sep 2010

Cancer-causing mutations have minimum effect on tumor growth: Research

Individual cancer causing mutations have a minute effect on tumor growth, increasing the rate of cell division by just 0.4 percent on average, according to new mathematical modeling by scientists at Harvard University, Johns Hopkins University, and other institutions.

29 Sep 2010

U-M experts clear confusion over mammography screening controversy

A year after a government panel revised its recommendations for breast cancer screening, many professional organizations have not followed suit.

29 Sep 2010

Medical Condition News

SCT transplantation benefits in Hodgkin's lymphoma is unclear

ACT updates myoblast program for heart failure treatment

USFDA grants Sun Pharma subsidiary tentative approval for generic Crestor ANDA

Study shows blueberries may help fight atherosclerosis

Duke receives approval to initiate NPC-1C Phase I trial for advanced pancreatic and colorectal cancer

Stress-factors leading to mental problems and burnout in IT-industries

Scientists discover gut stem cells replacement mechanism

New immunotherapy regimen improves survival rate in children with neuroblastoma: Research

UNC scientists receive grant to develop targeted delivery system for pancreatic cancer

Michigan University researchers receive funds to study breast cancer risk factors

Memantine enhances language and communication skills in patients with Alzheimer's disease

Circadian partners with Cincinnati Children's Hospital to develop blood test diagnostic for LAM, a serious lung disease

Keryx commences Zerenex Phase 3 study for hyperphosphatemia in patients with ESRD on dialysis

NINDS establishes new sites as part of Morris K. Udall Centers of Excellence in Parkinson's Disease Research

Rigel earns $25M milestone payment from Astrazeneca for clinical development of fostamatinib

IN.PACT drug-eluting balloons show promising results for superficial femoral artery disease treatment

Pulmokine receives NIH SBIR grants to develop novel treatments for PAH

XOMA completes patient enrollment in XOMA 052 Phase 2a trial

Cancer-causing mutations have minimum effect on tumor growth: Research

U-M experts clear confusion over mammography screening controversy

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Latest News